Our meeting with the FDA yesterday was very productive, and we remain on track for an NDA filing of CTx-1301 in mid-2025. We truly appreciate the FDA personnel who have been involved with the ...

Fette Compacting is on a successful path and presents itself confidently as a strategic partner for the pharmaceutical and ...

MCC is extensively utilized in the pharmaceutical industry as a disintegrant and bulking agent for tablet formulations, ...

RediClinic’s DiaControl Supplement stands out as a promising natural solution for managing sugar levels, thanks to its ...

The RediClinic Glutathione supplement offers promising benefits for skin brightening, anti-aging, and detoxification, its ...

Q4 2024 Earnings Call Transcript March 31, 2025 Alpha Cognition Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.51 EPS, expectations were $-0.48. Operator: Greetings, and ...

Japanese drugmaker Chugai (TYO: 4519) has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) ...

A new tablet formulation of SMA treatment Evrysdi (risdiplam) may give patients more "freedom and independence," a Genentech ...

Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces positive interim results from its randomized, double-blind, placebo-controlled Phase Ib single subcutaneous (SQ) injection study ( ...

The National List of Essential Medicines includes crucial medicines used in different scenarios, including drugs used for ...

Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...